Picture of PAVmed logo

PAVM PAVmed Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+15.25%
3m-41.93%
6m-56.34%
1yr-64.39%
Volume Change (%)
10d/3m-57.88%
Price vs... (%)
52w High-73.08%
50d MA-6.88%
200d MA-40.01%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-5297.69%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of PAVmed EPS forecast chart

Profile Summary

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
June 26th, 2014
Public Since
July 27th, 2016
No. of Shareholders
214
No. of Employees
124
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
8,050,659.07

PAVM Share Price Performance

Upcoming Events for PAVM

Q4 2023 PAVmed Inc Earnings Release

Q4 2023 PAVmed Inc Earnings Call

Q1 2024 PAVmed Inc Earnings Release

PAVmed Inc Annual Shareholders Meeting

Q2 2024 PAVmed Inc Earnings Release

Similar to PAVM

Picture of Accelerate Diagnostics logo

Accelerate Diagnostics

us flag iconNASDAQ Capital Market

Picture of Acutus Medical logo

Acutus Medical

us flag iconNASDAQ Capital Market

Picture of Adapthealth logo

Adapthealth

us flag iconNASDAQ Capital Market

Picture of Aethlon Medical logo

Aethlon Medical

us flag iconNASDAQ Capital Market

Picture of Agape ATP logo

Agape ATP

us flag iconNASDAQ Capital Market

FAQ